Bayer's pharma, consumer sales suffer in Q3 as it works to close Monsanto deal

26th October 2017 Uncategorised 0

Some analysts and market watchers worried about Bayer’s focus when the drugmaker went after agrochem giant Monsanto in a $66 billion deal last year, and now the company’s third-quarter results are sparking more concern.

More: Bayer's pharma, consumer sales suffer in Q3 as it works to close Monsanto deal
Source: fierce